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Abstract
Background: Home delivery of antiretroviral therapy (ART) by community health workers (CHWs) may improve
ART retention by reducing the time burden and out-of-pocket expenditures to regularly attend an ART clinic. In
addition, ART home delivery may shorten waiting times and improve quality of care for those in facility-based care
by decongesting ART clinics. This trial aims to determine whether ART home delivery for patients who are clinically
stable on ART combined with facility-based care for those who are not stable on ART is non-inferior to the standard
of care (facility-based care for all ART patients) in achieving and maintaining virological suppression.
Methods: This is a non-inferiority cluster-randomized trial set in Dar es Salaam, Tanzania. A cluster is one of 48 healthcare
facilities with its surrounding catchment area. 24 clusters were randomized to ART home delivery and 24 to the standard
of care. The intervention consists of home visits by CHWs to provide counseling and deliver ART to patients who
are stable on ART, while the control is the standard of care (facility-based ART and CHW home visits without ART
home delivery). In addition, half of the healthcare facilities in each study arm were randomized to standard
counseling during home visits (covering family planning, prevention of HIV transmission, and ART adherence), and half
to standard plus nutrition counseling (covering food production and dietary advice). The non-inferiority design applies
to the endpoints of the ART home delivery trial; the primary endpoint is the proportion of ART patients at a healthcare
facility who are virally suppressed at the end of the study period. The margin of non-inferiority for this primary
endpoint was set at nine percentage points.
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Discussion: As the number of ART patients in sub-Saharan Africa is expected to rise, this trial provides causal evidence
on the effectiveness of a home-based care model that could decongest ART clinics and reduce patients’ healthcare
expenditures. More broadly, this trial will inform the increasing policy interest in task-shifting of chronic disease care
from facility- to community-based healthcare workers.
Trial registration: ClinicalTrials.gov: NCT02711293. Registration date: 16 March 2016.
Keywords: Antiretroviral therapy, HIV, Community health workers, Nutrition counseling, Food production, Adherence,
Retention, Healthcare expenditure
Background
An estimated 37% of the 24.7 million people living with
the human immunodeficiency virus (HIV) in sub-Saharan
Africa (SSA) were receiving antiretroviral therapy (ART)
in 2015 [1, 2]. Since the advent of antiretroviral drugs, the
World Health Organization (WHO) has gradually in-
creased the recommended threshold for ART initiation
from a CD4-cell count of less than 200 cells/μL in 2006
[3], to less than 350 cells/μL in 2010 [4], and less than
500 cells/μL in 2013 [5]. Most recently, in 2015, the
WHO has recommended immediate ART for all people
living with HIV, irrespective of CD4 count [6]. As coun-
tries expand ART eligibility– and because ART in-
creases the life expectancy of people living with HIV –
the number of people needing ART in SSA is likely to
increase substantially over the coming decades [6, 7].
However, the financial, human and physical resources
available to deliver ART are unlikely to grow in propor-
tion to this increase. These developments call for new
models of care that increase the capacity and efficiency
of delivering ART without reducing quality of care [8].
The importance of ART retention and adherence
The benefits from the scale-up in ART coverage will
critically depend on life-long ART retention and adher-
ence. A meta-analysis pooling ART adherence data
from over 30,000 adult patients in 84 observational
studies across 20 countries found that 38% of patients
took less than 90% of prescribed ART doses [9]. Simi-
larly, previous analyses by our team in a cohort of over
44,000 patients in Dar es Salaam’s adult HIV treatment
and care program have found low ART retention and
adherence. More specifically, we found that 39% of
adults on ART were lost to follow-up within 12 months
of initiation (unpublished data). In addition, 19% were
non-adherent to ART [10] (as defined by non-
compliance with scheduled ART pickup visits of greater
than 5%) at any given point in time, with the risk of
non-adherence increasing with duration on ART.
Worryingly, the risk of non-adherence also rose inde-
pendently with increasing calendar year, with the relative
risk (RR) of non-adherence being 2.0 (95% confidence
interval: 1.9-2.1) in 2010 compared to the reference year
2004. Poor adherence is not only likely to lead to treatment
failure and resulting morbidity and mortality, but also in-
creases the risk of HIV transmission and, crucially, the de-
velopment of resistant HIV strains [11–13]. Increasing
ART resistance may narrow future antiretroviral drug op-
tions, and thus reduce ART access and increase the cost of
effective HIV treatment as programs have to move to more
expensive second and third-line regimens.
Reasons for community health worker-led home delivery
of ART to improve retention and adherence
In a large qualitative study in three urban settings in
sub-Saharan Africa, including Dar es Salaam, Ware et al.
found that the main unintentional reason for missed
ART clinic visits was a lack of time due to other, often
unexpected, events in a patient’s life [14]. In addition,
many studies have identified the cost to patients of
attending ART clinics (not just expenses on user fees
but also on transport, food, and lost income [14–18]),
transport-related factors [19], and long clinic waiting
times [14] as being important barriers to ART reten-
tion. Given that the delivery of ART at home through
community health workers (CHWs) would overcome
many of these barriers, CHWs have the potential to
significantly improve ART retention and adherence.
An additional benefit of a home-based approach to
ART arises from the resulting reduced patient load at
ART clinics, which may decrease waiting times and im-
prove quality of care as facility-based healthcare workers
have more time available per patient. The home delivery
of ART by CHWs is, therefore, not merely an intervention
aimed at improving ART retention and adherence but also
a measure that can shift care from more highly to less
well-trained health workers. Such task-shifting measures
may therefore alleviate the severe shortage of human re-
sources for health in SSA, which is a central barrier to
attaining universal coverage of HIV services [20, 21].
The WHO has identified 313 tasks, which are essential
for the prevention of HIV transmission, identification of
HIV-infected individuals, provision of basic HIV-related
clinical management, and initiation and maintenance of
patients on ART. The WHO recommends that 115 of
these tasks, including the dispensing of ART, can be
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performed by CHWs, highlighting the immense potential
of task-shifting for HIV-related care [22].
The current evidence base for home delivery of ART by
community health workers
A systematic review of health service delivery for ART
provision identified two randomized trials, which evalu-
ated ART home-delivery programs [23]. Both of these
trials randomized geographical areas around one ART
clinic. The first trial was set in rural Uganda and random-
ized areas to either home delivery of ART by field officers,
or standard facility-based ART [24]. The participants were
patients newly initiated on ART. The trial found no differ-
ence between study arms in the rate of virological failure
or mortality, neither after six months [24] nor at 36-
months follow-up [25]. The median expense to patients
in terms of transport costs, food, child care, and lost
work time due to ART utilization was higher in the
facility-based group than in the home-based group at
US$60 versus US$29 in the first year, and US$54 versus
US$18 in subsequent years. In addition, the median cost
to the health system per patient per year was somewhat
lower in the CHW group (US$793) than in the facility-
based group (US$838) as the increased transport costs for
CHWs were offset by patients’ reduced clinic attendance.
In another study, the same cohort of patients receiving
ART home delivery was compared with ART patients
who attended a physician-staffed hospital in an urban
sub-district of Uganda [26, 27]. While comparability of
the two cohorts is limited by the observational study
design, the study found that community-based participants
were more likely to achieve viral suppression (after
adjusting for CD4-count at baseline and socio-demographic
characteristics), and there was no difference in all-cause
mortality. The second randomized trial was carried out in
rural Kenya and, similar to the Uganda study, found no dif-
ference in the percentage of patients with an undetectable
viral load, mean CD4-count, incidence of opportunistic
infections, and change in ART regimen between stable
ART patients who received ART from CHWs during home
visits, as compared to patients randomized to standard
facility-based ART [28].
This trial differs in several crucial aspects from the
two studies described above. Firstly, this trial is the first
to evaluate ART home delivery in an urban setting. Sec-
ondly, this is a health systems trial, which implements the
intervention directly into the routine healthcare system.
Both the Uganda and Kenya trial randomized geographic
areas around one clinic run by a non-governmental
organization [24, 28], while this study is being imple-
mented at all healthcare facilities in Dar es Salaam that
offer ART and have an affiliated team of public-sector
CHWs. In addition, while the Uganda trial trained a new
cadre of field officers to deliver ART by motorbike and the
Kenya trial trained ART patients at the clinic to act as
community care coordinators, this trial is utilizing a large
existing public-sector CHW program in Dar es Salaam.
Thirdly, this trial includes a large number (24) of healthcare
facilities in each study arm, while both the Uganda and
Kenya trial implemented the intervention at only one
clinic. Aside from external validity concerns arising from a
study carried out in a single clinic, an important disadvan-
tage of drawing the intervention and control group from
the same healthcare facility is that ART home delivery is
likely to have affected the care provided to the control
group, as the shifting of patients to community-based care
substantially reduced the patient volume at the facility.
Such shifts may have resulted in the control group being a
poor counterfactual. Finally, both the Uganda and Kenya
trial were unable to rigorously assess the effect of shifting
patients to the community on routine facility-based ART.
This trial, on the other hand, will be able to compare pa-
tient satisfaction, time spent by nurses and physicians with
ART patients, and clinicians’ job satisfaction between the
24 intervention and 24 control facilities.
This non-inferiority cluster-randomized trial evaluates
the feasibility and effectiveness of CHW-led home delivery
of ART in the public-sector healthcare system of Dar es
Salaam, the largest city in Eastern Africa. More specifically,
this study aims to determine whether a differentiated ART
care model (ART home delivery for patients who are
clinically stable on ARTand standard facility-based care for
those who are not stable on ART) is non-inferior to the
standard of care (facility-based care for all ART patients) in
achieving and maintaining virological suppression.
Methods/design
Study setting
The study will be implemented in all three municipal-
ities (Ilala, Kinondoni, and Temeke) of the Dar es
Salaam region of Tanzania, which contains the city of
Dar es Salaam. The average household size in the Dar es
Salaam region is 4.0 people and is virtually the same
across its three municipalities (ranging from 3.9 to 4.0).
Dar es Salaam’s HIV prevalence was 6.9% among adults
aged 15–49 years in 2012, which is above the national
prevalence of 5.1% [29].
The home-based carer program
This trial utilizes an existing and long-standing public-
sector CHW cadre, called home-based carers or HBCs,
to deliver the intervention. The CHWs are employed by
Dar es Salaam’s municipalities and receive a stipend of
80,000 Tanzanian shilling (approximately equal to 36 US
dollars) per month. They are lay healthcare workers whose
main responsibility is to conduct regular home visits (at
least once every three months) to all households in the
neighborhood to which they have been assigned. The
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precise tasks of the CHWs during these home visits
have varied somewhat over the years but generally con-
sist of the provision of information and counseling on a
wide variety of health topics, referral of ill clients to
healthcare facilities, and promotion of preventive health-
care services. The CHW program exists in most but not
all areas of Dar es Salaam. In those areas where the CHW
program has been implemented, each neighborhood has
one to three CHWs. The CHWs are residents in the
neighborhoods in which they work.
Study duration
Enrolment into the trial took place in facilities in the
Temeke municipality from February 29th 2016 to July
29th 2016. Because the number of participants enrolled
in Temeke was lower than expected, the trial was ex-
panded to 16 healthcare facilities in the Kinondoni mu-
nicipality and 14 facilities in the Ilala municipality.
Enrolment in Kinondoni took place from August 1st 2016
to November 11th 2016, and enrolment in Ilala from
November 14th 2016 to January 20th 2017. The study
activities during the trial period are detailed in Fig. 1.
Eligibility criteria
The eligibility criteria for participants in this trial are: 1)
being aged 18 years or older; 2) attending one of the par-
ticipating healthcare facilities for ART during the enrol-
ment period; and 3) living in a neighborhood in the
facility’s catchment area. An additional eligibility criterion
for ART home delivery is being clinically stable on ART.
A patient is clinically stable on ART if the patient’s most
current viral load has been taken less than 12 months
prior to enrolment and showed viral suppression. If a viral
load measurement is unavailable at the time of enrolment
but a CD4-cell count taken in the 12 months prior to
enrolment is available, then a patient is clinically stable on
ART if the most current CD4-cell count is >350 cells/μL.
If neither a viral load nor a CD4-count taken in the
12 months prior to enrolment is available, then a venous
blood sample will be taken for a viral load measurement
and the result used for the eligibility assessment. Add-
itional requirements for being stable on ART are 1) taking
ART for at least six months, and 2) having had a CD4-cell
count >350 cells/μL or a suppressed viral load at six or
more months after ART initiation. Patients who are preg-
nant at the time of enrolment (by patient self-report) or
unable to provide written informed consent (e.g., due to
mental incapacity) are excluded from eligibility.
Study design
Rationale for a non-inferiority design and margin of
non-inferiority
The non-inferiority design only applies to the primary
endpoint (the proportion of participants with a suppressed
HIV viral load). This design choice was made because in
settings with an existing CHW program, such as in Dar es
Salaam, CHW-led home delivery should likely be the
standard of care if it does not negatively affect patients’
health outcomes as compared to standard facility-based
care. Two virtually certain benefits of CHW-led ART
home delivery are a reduction in 1) patient volume at
healthcare facilities, which helps to alleviate the severe
shortage of skilled healthcare workers in sub-Saharan
Africa [20], and 2) the substantial time and financial (e.g.,
transport costs) burden on patients of having to attend an
ART facility [24, 30]. The main drawback of CHW-led
ART home delivery is the cost of establishing and running
the CHW program, and the risk of overburdening CHWs,
which may lead to a reduction in quality and/or quantity
of care for non-ART patients. We would argue that in the
case of Dar es Salaam, the cost consideration is minor as
the CHW program already exists and is likely continue to
run independently of whether CHWs are tasked with
ART home delivery. Regarding overburdening CHWs, we
carefully monitor the number of visits made by CHWs to
non-HIV patients in each study arm and also ascertain
CHWs’ job satisfaction and perception of the intervention
through semi-structured qualitative interviews.
Based on our own judgement of what constitutes
non-inferiority for this intervention and in line with the
margin of equivalence of nine percentage points used
by Jaffar et al. in their randomized trial of ART home
delivery in rural Uganda [24], we chose a margin of
non-inferiority of nine percentage points.
Randomization
The unit of randomization is a healthcare facility with its
surrounding catchment area (Fig. 2). Which healthcare
facilities were included in this study was determined by
the supervisory structure of CHWs in the routine
public-sector health system. Each CHW is supervised by
one community outreach nurse who is a nurse based at
a healthcare facility. Each community outreach nurse su-
pervises between three and 16 CHWs who work in neigh-
borhoods (mtaa in Kiswahili) in the facility’s catchment
area. We included all healthcare facilities in Dar es
Salaam in this trial, which provide ART and had a
community outreach nurse (and thus a team of affili-
ated CHWs) with the exception of two facilities
(Amana Hospital and Mwananyamala District Hospital)
because of a conflict with a clinical trial taking place at
these facilities. Table 1 describes the characteristics of
each cluster.
For the purposes of randomization, clusters were first
matched into pairs, separately within each municipality,
based on the number of patients currently on ART at
the facility. More specifically, the facility with the highest
number of ART patients in Temeke was paired with the
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Fig. 1 Trial activities over the study period
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facility with the second highest number of ART patients
in Temeke, and so on. The reason for this choice was
that the intervention becomes more complex and thus
plausibly less feasible to implement with an increasing
volume of eligible participants. Most facilities only have
one community outreach nurse. Thus, with an increas-
ing number of eligible participants (for which ART pa-
tient volume is a proxy), the number of patients for
whom the community outreach nurse has to supervise
ART home delivery increases. An added benefit of
matching on size prior to randomization is that it ensured
an approximately equal number of participants in each
study arm. The same process of matching facilities into
pairs based on ART patient volume was used to
randomize half of the facilities in each study arm to
standard counseling and half to standard plus nutrition
counseling (Fig. 1). The study design is thus a matched-
pair cluster-randomized controlled 2x2 factorial trial. The
randomization was conducted prior to the start of the
study using computer-generated random numbers. For
feasibility reasons, neither the research team nor the study
participants are blinded to the intervention assignment.
Enrolment procedure
One to two study team members (henceforth referred to as
data collectors) are placed full-time at each of the partici-
pating healthcare facilities for the duration of the enrolment
period. The ART nurse at each of the participating health-
care facilities referes all ART patients who live in the
facility’s catchment area to the data collector. The data col-
lector introduces the study to the patient, and, provided
the patient gives initial verbal consent, ascertains whether
the patient is 1) stable on ART (see eligibility criteria), and
2) lives in the facility’s catchment area. If both criteria are
fulfilled, the data collector conducts the written informed
consent procedure, administers a tablet-based baseline
questionnaire, and measures the participant’s height and
weight. Next, the data collector asks the community out-
reach nurse at the facility to take a blood sample, which is
sent for a measurement of blood hemoglobin. In addition,
the blood sample is sent for an HIV viral load in partici-
pants who have not had a viral load measurement in the
12 months prior to study enrolment. Lastly, the data
collector takes a map cue (a description of the location of
the participant’s residence) from the participant and
records his/her mobile phone number as well as the
mobile phone number from at least one household mem-
ber. These details are then passed to the CHW assigned to
the neighborhood, in which the participant lives.
Description of the interventions
Home delivery of ART
In clusters randomized to ART home delivery, a CHW
visits participants at home to provide counseling (see
below), deliver a supply of ART, and perform an ART
pill count. After a year on ART, most patients in Dar es
Salaam are scheduled to attend the facility every two
months. We maintain a participant’s usual facility ART
schedule in the ART home-delivery intervention. For
instance, an ART patient who was scheduled to visit the
facility every two months (and was provided with a two-
months ART supply) receives a CHW visit for ART
home delivery every two months (and receives a two-
months ART supply from the CHW). The CHWs re-
ceived three days of training in the home delivery of
ART and in counseling skills for this intervention prior
to the start of the trial.
Nutrition counseling
CHWs provide counseling to all participants in both the
intervention and control arms during their home visits.
As described in the study design section, half of the clusters
in each the intervention and control arm of the trial were
randomized to standard counseling, and half to standard
plus nutrition counseling. The standard counseling covers
family planning, ART adherence, and prevention of HIV
transmission. Nutrition counseling covers advice on 1) food
production for those with access to a garden or plot of
land, 2) a healthy diet for people living with HIV, 3) ex-
ercise, and 4) monitoring one’s weight. In addition,
Fig. 2 Randomization scheme
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Table 1 Characteristics of the clusters
Name of healthcare facility Counseling packagea Type of healthcare facility Municipality No. of patients currently
on ART
No. of CHWs in cluster
ART home delivery
1. Mbagala Rangi Tatu Standard + nutrition Hospital Temeke 15,663 3
2. Tambukareli Standard Dispensary Temeke 1,554 12
3. Yombo Makangarawe Standard Dispensary Temeke 544 2
4. Toa Ngoma Standard + nutrition Dispensary Temeke 239 12
5. Buza Standard + nutrition Dispensary Temeke 215 5
6. Arafa Ugweno Standard Dispensary Temeke 202 3
7. Mji mwema Standard Dispensary Temeke 161 8
8. Kimbiji Standard + nutrition Dispensary Temeke 119 6
9. Keko Standard + nutrition Dispensary Temeke 79 4
10. Tandale Standard Dispensary Kinondoni 2,951 9
11. Mburahati Standard + nutrition Dispensary Kinondoni 1,639 11
12. Mwenge Standard Dispensary Kinondoni 1,597 5
13. Mbezi Standard + nutrition Dispensary Kinondoni 870 11
14. Hananasif Standard + nutrition Dispensary Kinondoni 530 7
15. Kigogo Standard Dispensary Kinondoni 347 3
16. Mabibo Standard + nutrition Dispensary Kinondoni 278 9
17. Goba Standard Dispensary Kinondoni 177 4
18. Tabata Standard Health Centre Ilala 2,193 10
19. Vingunguti Standard + nutrition Health Centre Ilala 1,865 7
20. Kitunda Standard + nutrition Health Centre Ilala 768 10
21. Pugu Kajiungeni Standard Dispensary Ilala 561 11
22. Tabata NBC Standard + nutrition Dispensary Ilala 249 10
23. Kinyerezi Standard Dispensary Ilala 238 13
24. Mongolandege Standard Dispensary Ilala 152 16
Total: 33,191b 191
Standard of care
1. Temeke Standard + nutrition Hospital Temeke 17,409 3
2. Kigamboni Standard Health Centre Temeke 2,879 9
3. Mbagala Round Table Standard + nutrition Dispensary Temeke 850 5
4. Maji Matitu Standard Dispensary Temeke 540 7
5. Kichemchem Standard + nutrition Dispensary Temeke 211 3
6. Kingugi Standard Dispensary Temeke 166 6
7. Sandali Standard Dispensary Temeke 148 9
8. Kibada Standard + nutrition Dispensary Temeke 109 8
9. Kisarawe II Standard Dispensary Temeke 63 5
10. Magomeni Standard + nutrition Health Center Kinondoni 2,361 8
11. Kimara Standard Dispensary Kinondoni 2,270 5
12. Bunju Standard + nutrition Dispensary Kinondoni 1,595 7
13. Kawe Standard Dispensary Kinondoni 844 5
14. Kijitonyama Standard + nutrition Dispensary Kinondoni 750 8
15. Kinondoni Standard Hospital Kinondoni 396 5
16. Makuburi Standard Dispensary Kinondoni 256 4
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participants enrolled in the trial at one of the health-
care facilities randomized to the nutrition counseling
intervention receive a pack of seeds (amaranth, cowpea,
or pumpkin) at enrolment if they report to have access
to a garden or plot of land where they can grow vegeta-
bles for their own consumption.
Endpoints
The primary endpoint for the ART home delivery inter-
vention is the proportion of enrolled patients with a sup-
pressed HIV viral load at the end of the study period
(i.e., when the study exit assessment is performed). A
substantial proportion of participants does not have a re-
cent viral load or CD4-cell count at enrolment. As de-
scribed above, the study team obtains a blood sample
from these patients at enrolment and sends it to the pub-
lic healthcare system’s laboratory for a viral load measure-
ment. Because the delay in receiving the viral load count
from the laboratory varies between participants (and thus,
the time point at which eligibility for ART home delivery
can be assessed at intervention facilities), the length of
time for which intervention participants receive ART at
home varies between participants at a healthcare facility.
Participants in the ART home-delivery intervention re-
ceive ART at home for a period varying between one and
11 months, and for an average of six months.
The primary endpoint for the nutrition counseling
intervention is the mean BMI of participants who re-
ceived standard counseling by CHWs versus those who
received standard plus nutrition counseling, assessed at
the end of the study period. Secondary endpoints of
this trial (all assessed at the end of the study period)
are: 1) participants’ healthcare expenditures in the last
six months, 2) self-reported ART adherence during the
last one month, 3) the proportion of patients with ac-
cess to a plot of land who grow vegetables or fruits for
their own consumption, 4) diversity of dietary intake,
and 5) the proportion of participants who are anemic.
Sample size
Over the enrolment period, we expect to recruit approxi-
mately 700 participants in each of the two trial arms
(1,400 participants in total). We calculated the design
effect (taking into account clustering of outcomes at the
facility-level and varying cluster sizes) for this trial using
the ‘clustersampsi’ function in Stata [31]. The design effect
was then used to adjust the expected power calculated for
a non-inferiority trial under individual randomization,
which we determined using the ‘ssi’ function in Stata [32].
Our calculations assumed that 85% of enrolled partici-
pants are virally suppressed at baseline as found in a re-
cent cross-sectional study in Dar es Salaam [33]. The
margin of non-inferiority was set at nine percentage
points. We used a range of intra-cluster correlation co-
efficients (ICCs) from 0.005 to 0.020. Barnhart et al.
calculated ICC values for CD4-cell count measures in
Dar es Salaam [34]. The 6-months cumulative incidence
for non-adherence to ART (defined as a 50% drop in
CD4-count from its peak value and return to pre-ART
CD4-count or lower after 168 days on ART or a viral load
greater than 10,000 after 168 days on ART) had an ICC
value of 0.016 (95% confidence interval: 0.009 to 0.029).
We set the probability of a type one statistical error at
0.05 and assumed a correlation coefficient between base-
line and endline viral load measurement of 0.5. We find
that we are well powered (≥80% power) to detect modest
one-sided differences (<9 percentage points) in the pro-
portion of participants who are virally suppressed between
the two study arms. Regarding the effect of nutrition
counseling on BMI, we are well powered (≥80%) to detect
a difference in mean BMI of approximately 1.0 kg/m2
or more between the participants in the standard ver-
sus the standard plus nutrition counseling arm. This dif-
ference is considerably smaller than the difference of
3.1 kg/m2 found by Alo et al. between female ART pa-
tients randomized to six months of nutrition counseling
versus the standard of care in Southeast Nigeria [35]. The
Table 1 Characteristics of the clusters (Continued)
17. Ununio Standard + nutrition Dispensary Kinondoni 115 6
18. Mnazi Mmoja Health Centre Standard + nutrition Health Centre Ilala 3,650 4
19. Chanika Standard Health Centre Ilala 1,413 12
20. Segerea Standard Health Centre Ilala 678 8
21. Kiwalani Standard + nutrition Dispensary Ilala 519 13
22. Gerezani Standard Dispensary Ilala 350 2
23. Majohe Standard + nutrition Dispensary Ilala 220 10
24. Mvuti Standard + nutrition Dispensary Ilala 185 16
Total: 37,977b 168
Abbreviations: ART antiretroviral therapy, No. number, CHW community health worker
a Half of the clusters in each study arm were randomized to standard counseling and half to standard plus nutrition counseling.
b This is not the expected number of participants as many ART patients do not live in the cluster (i.e., in the area surrounding the healthcare facility), and are
therefore not eligible for this trial
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trial by Alo et al. is, to the best of our knowledge, the only
randomized evaluation to date of the impact of nutrition
counseling on BMI in ART patients.
Data collection
This trial is being implemented by Management and
Development for Health (MDH). MDH is a Tanzanian
non-governmental organization based in Dar es Salaam,
which works closely with Tanzania’s Ministry of Health
and Social Welfare. MDH is working on this trial in
partnership with the Harvard T.H. Chan School of Public
Health, which provides technical assistance throughout
the study period.
Biomarkers
HIV viral load and hemoglobin are measured at baseline
and at the end of the study period. If a participant has
had a viral load measurement in the 12 months prior to
study enrolment, this measurement will be used as the
baseline viral load.
Questionnaires
The study’s team of trained data collectors administers a
tablet-based questionnaire at enrolment, and then
again at the end of the study period. This questionnaire
(see Additional file 1) covers self-reported ART adherence,
health service utilization, out-of-pocket healthcare expen-
ditures, satisfaction with CHW services, knowledge of
HIV, utilization of family planning methods, dietary in-
take, physical activity, and food production. In addition,
the data collectors administer a questionnaire during the
enrolment period and during the follow-up period at each
participating healthcare facility to a random set of patients
after they have accessed an HIV service (i.e., HIV-testing,
pre-ART, or ART). This questionnaire (see Additional file 2)
asks about patient satisfaction with HIV-related healthcare
services, time spent in the facility for the present visit, health
service utilization and expenditure, and self-reported
ART adherence. Patients for this questionnaire are se-
lected using the sampling method of selecting the next
patient entering the consultation [36]. Lastly, a healthcare
provider questionnaire is administered to a random set of
healthcare workers at each participating healthcare facility
during the enrolment period and the follow-up period of
the trial. This questionnaire (see Additional file 3) covers
job satisfaction, perceived time pressure, and healthcare
workers’ views on home delivery of ART.
Qualitative data collection
During the enrolment period and at the end of the study
period, data collectors trained in qualitative interviewing
will conduct semi-structured qualitative interviews with
community outreach nurses, CHWs, and participants in
the ART home-delivery arm. These interviews aim to
ascertain healthcare workers’ and participants’ experi-
ences with ART home delivery, and their suggestions
for improvement in the delivery of the intervention. In
addition, semi-structured qualitative interviews will be
conducted with patients who were offered ART home
delivery, but refused to enroll in ART home delivery, to
identify their reasoning for preferring facility-based
ART.
Data monitoring
The ability for data monitoring in this trial is limited by
the fact that no outcome data is collected on participants
during the follow-up period. However, the follow-up
period has intentionally been designed to be compara-
tively short so that in the case of ART home delivery
resulting in considerably lower viral load suppression than
facility-based care, the adverse effects on patients’ health
are relatively minor. We do not expect adverse effects on
patients’ health from this intervention given the encour-
aging results from the trials in Uganda [24] and Kenya
[28]. Further, participants in the ART home delivery arm
can opt to switch back to facility-based care at any time
during the trial period. This trial therefore does not have a
data safety and monitoring board.
Analysis plan
We will analyze the data by intention-to-treat analysis
at the patient level in all primary analyses for this trial.
The primary endpoint of this trial (i.e., the percentage
of participants with a suppressed HIV viral load at the
end of the study period) will be assessed by fitting ro-
bust clustered log-binomial models. Given the rela-
tively small number of clusters in this trial, we cannot
assume that randomization will eliminate confounding
despite the matching of clusters described in the study
design section. We will, therefore, adjust the analysis
for viral load suppression at baseline. As viral load
suppression is the outcome variable for the primary
endpoint, adjusting for baseline viral load could be
considered perfect adjustment for confounders. How-
ever, in secondary analyses, we will also adjust for
other potentially confounding variables (e.g., partici-
pants’ socio-demographic characteristics) as a single
baseline measurement may not account for trends in
viral load suppression over time. Similarly, in second-
ary analyses, we will adjust for differing average expos-
ure lengths to ART home delivery at each facility, and
conduct subgroup analyses according to whether a
participant received ART home delivery and by partic-
ipants’ exposure length to ART home delivery.
Potential effect modification for any of the end-
points of this trial will be assessed through the likeli-
hood ratio test. If statistically significant effect
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modification is present, we will present relevant re-
sults stratified by the effect modifier. All analyses will
be conducted using Stata (Release 13; StataCorp,
College Station, TX, USA).
Ethical considerations
Approvals
The study was approved by the research ethics committee
of the National Institutes of Medical Research (NIMR) in
Tanzania on July 16th 2015 and received an exemption by
the institutional review board of the Harvard T.H. Chan
School of Public Health in June 2015. NIMR will be in-
formed immediately of any study protocol amendments
and the trial registers (RIDIE and ClinicalTrials.gov)
will be updated accordingly.
Consent
The data collectors placed at each of the study’s healthcare
facilities will obtain written informed consent from all par-
ticipants at enrolment into the study. To adhere to the
intent-to-treat principle, patients who refuse to participate
in the study at any time during the study period, including
during enrolment, will be asked for consent to complete
the study questionnaire, and to take a blood sample and
BMI measurement at enrolment and at the end of the
study period. The data collectors will also obtain written
informed consent from respondents before administering
the patient exit questionnaire and the healthcare provider
questionnaire.
Confidentiality
CHWs were instructed to seek a private space in the
participant’s home before providing counseling and
delivering ART. In addition, potential participants will
be asked about whether they have disclosed their HIV
status to other household members during enrolment.
CHWs will be informed which participants have not
disclosed their HIV status to all other household members
and be urged to make an utmost effort to maintain the
participant’s privacy during their home visits. Similarly,
the patient exit and healthcare provider questionnaire will
be administered in a space that maximizes the respon-
dent’s privacy.
Access to data
The research team at MDH will have access to the full
datasets collected as part of this study at all times during
the trial. The MDH team will share de-identified data-
sets with the investigators at the Harvard T.H. Chan
School of Public Health on a regular basis.
Dissemination of results
The trial results will be disseminated through personal
meetings with policy makers in Dar es Salaam, including
the municipal leadership and the Tanzanian Ministry of
Health and Social Welfare. In addition, the results will
be submitted for publication in a peer-reviewed scientific
journal and presented at scientific conferences.
Trial status
Enrolment into the trial has commenced on February
29th 2016 and is currently ongoing.
Discussion
Most low- and middle-income countries (LMICs) face a
severe shortage of nurses and physicians [1], and distance
to the nearest healthcare facility is a key barrier to accessing
care in many regions [37–40]. Thus, the potential benefits
of shifting care from skilled facility-based health worker
cadres to lay community-based healthcare workers are evi-
dent. While this trial focuses on HIV care, it will contribute
to a growing body of evidence on a broader question that is
central to current health systems implementation research:
what is the acceptability and feasibility of shifting care from
facility-based nurses and physicians to lay healthcare
workers based in the community, and what is the effect
on patients’ health and economic outcomes? The ques-
tion of whether drugs for chronic diseases can be safely
provided by CHWs is one that is becoming increasingly
important as the burden of chronic non-communicable
diseases in LMICs grows [41]. The regular dispensing
of drugs for chronic diseases may be a good candidate
for task-shifting to CHWs for several reasons: 1) the
frequency of needing to return to a healthcare facility
to pick up medications may be determined by a facility’s
drug stocks rather than a need for clinical monitoring by a
nurse or physician, 2) there is a considerable cost to
patients, both in terms of time lost and out-of-pocket
expenditures [30], from having to regularly attend a
healthcare facility, and 3) non-retention in care is com-
mon in many chronic care settings in LMICs [42].
Limitations
This study has several limitations. First, there is the
possibility of selection bias whereby ART patients in a
control cluster may hear about the offer of ART home
delivery at intervention facilities. These patients may
change their care from a control to an intervention facility
in order to receive ART at home. To assess whether this is
a likely source of bias, we will ask patients at enrolment
where and when they have last received ART and, where
applicable, why they have changed healthcare facility. An
additional threat to the internal validity of this trial could
arise if a substantial portion of participants in the ART
home-delivery arm does not return to the facility at the
end of the follow-up period for a viral load measurement
and administration of the endline questionnaire. If the pa-
tients who are lost to follow-up in the ART home-delivery
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arm have systematically different outcomes (e.g., are less
likely to be virally suppressed) than patients who are not
lost to follow-up, and this difference or the rate of loss to
follow-up varies between the study arms, then this would
result in bias. To minimize this potential bias, we will
undertake additional efforts to collect viral load and BMI
data from participants in the ART home-delivery arm
who do not return to the healthcare facility at the end of
the follow-up period, including taking blood samples for
viral load measurement at participants’ homes. A limita-
tion to the external validity of this trial is that it focuses
on home delivery of ART for patients who are stable on
ART. home delivery of ART may, however, also be feasible
for patients who just initiated ART, or whose WHO clin-
ical stage, CD4-cell count or viral load suggests that they
are not stable ART patients. For example, in a sub-
analysis in patients who started ART with a low CD4-cell
count (<50 cells/μL) as part of the cluster-randomized
trial in Uganda described in the introduction, Woodd et
al. did not find an increased rate of mortality among those
who continued to receive ART at home after ART initi-
ation as compared to those who received standard clinic-
based care [43].
In conclusion, this is the first randomized health systems
implementation trial investigating the feasibility and effect-
iveness of CHW-led ART home delivery in urban sub-
Saharan Africa. The results of this trial will not only inform
ART programs in sub-Saharan Africa but also contribute
an important piece of evidence to the ongoing policy
debate on task-shifting of chronic care from facility- to
community-based healthcare workers.
Additional files
Additional file 1: Baseline Patient Questionnaire. (DOCX 314 kb)
Additional file 2: Patient Exit Questionnaire. (DOCX 325 kb)
Additional file 3: Healthcare Provider Questionnaire. (DOCX 142 kb)
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